By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


TrovaGene, Inc. 

11055 Flintkote Avenue

San Diego  California  92121  U.S.A.
Phone: 858-952-7570 Fax: n/a


Company News
TrovaGene (TROV)'s PLK1 Inhibitor PCM-075, In Preclinical AML Data, Significantly Enhances The Efficacy Of A FLT3 Inhibitor In Combination Therapy 8/16/2017 6:34:15 AM
TrovaGene (TROV) Announces Second Quarter 2017 Company Highlights and Financial Results 8/10/2017 1:04:09 PM
TrovaGene (TROV), Antonius Schuh And Stephen Zaniboni Resolve Employment Dispute 7/31/2017 1:27:04 PM
TrovaGene (TROV) Announces FDA Approval Of IND For Phase Ib/II Trial Of PCM-075 In Patients With Acute Myeloid Leukemia 7/27/2017 6:29:17 AM
TrovaGene (TROV) Announces Peer-Reviewed Publication Of First-In-Human Phase I Trial Results With PCM-075, Its Polo-Like Kinase 1 (PLK1) Inhibitor 7/25/2017 6:32:51 AM
TrovaGene (TROV) Announces $7.1 Million Registered Direct Offering 7/14/2017 9:12:34 AM
TrovaGene (TROV) Announces Agreement With Novogene For NextCollect In China 7/12/2017 6:57:46 AM
TrovaGene (TROV) Regains Compliance With NASDAQ Listing Requirements 7/10/2017 8:51:35 AM
TrovaGene (TROV) Engages Leading CRO In AML To Conduct Phase Ib/II Trial Of PCM-075 7/6/2017 6:43:58 AM
TrovaGene (TROV) Announces Manufacturing Agreement With NerPharMa For Supply Of PCM-075 For AML Trial 6/29/2017 7:31:06 AM